S
Sergey Kanaev
Researcher at Thomas Jefferson University
Publications - 7
Citations - 204
Sergey Kanaev is an academic researcher from Thomas Jefferson University. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 2, co-authored 3 publications receiving 173 citations.
Papers
More filters
Journal ArticleDOI
Magnetic resonance-guided focused ultrasound for patients with painful bone metastases: phase III trial results
Mark D. Hurwitz,Pejman Ghanouni,Sergey Kanaev,Dmitri Iozeffi,David Gianfelice,Fiona M. Fennessy,Abraham Kuten,Joshua E. Meyer,Suzanne LeBlang,Ann Roberts,Junsung Choi,James Larner,Alessandro Napoli,Vladimir Turkevich,Yael Inbar,Clare M. Tempany,Raphael Pfeffer +16 more
TL;DR: This multicenter phase III trial demonstrated that MRgFUS is a safe and effective, noninvasive treatment for alleviating pain resulting from bone metastases in patients that have failed standard treatments.
Journal ArticleDOI
MR-guided focused ultrasound for painful bone metastases: safety when combined with chemotherapy
Joshua E. Meyer,Raphael Pfeffer,Sergey Kanaev,Dmitri Iozeffi,David Gianfelice,Pejman Ghanouni,Daniela Militianu,Mark D. Hurwitz +7 more
TL;DR: A retrospective analysis of the safety of combination MRgFUS with active systemic chemotherapy in patients treated on this study found that the regimen was stable for at least 4 weeks.
Journal ArticleDOI
Focal MR-guided focused ultrasound treatment of localized low-risk prostate cancer
Alexandr Nosov,Vladimir Turkevich,Christopher Cheng,Andrey Vorobiev,Sergey Kanaev,Sergey Reva,Georg Gafton +6 more
TL;DR: Focal magnetic resonance guided intensity focused ultrasound treatment offers a novel strategy that targets the cancer rather than the prostate in an attempt to preserve tissue and function.
Journal ArticleDOI
Evaluation of the effectiveness of diagnostics and complex treatment of piriformis syndrome
TL;DR: The combination of classical manual therapy and the use of medical blockades with dynamic ultrasound control is a therapeutic choice in patients with primary and secondary piriformis syndrome.
Journal ArticleDOI
A comparison between high dose rate brachytherapy and stereotactic body radiotherapy boost after elective pelvic irradiation for high and very high-risk prostate cancer
Sergey Novikov,I. V. Novikov,Yurii Olegovich Merezhko,Mariya Yurevna Gotovchikova,Nikolai Dmitrievich Ilin,Y. Melnik,Sergey Kanaev +6 more
TL;DR: The results indicate similar 3- and 5-year BRFS in patients with high/very high-risk prostate cancer who received HDRB or SBRT boost, but S BRT boost is associated with higher rate of severe late rectal toxicity.